A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

Presented at the American College of Rheumatology on November 10, 2019

Presented at the American Society of Clinical Psychopharmacology on May 29, 2019

Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)

Differential Treatment Effects of a Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD

Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies

Presented at the 2018 Military Health System Research Symposium in Kissimmee, FL August 20 – 23

Poster Discussion Session: Innovations in PTSD Treatment Research

Gregory Sullivan, R Michael Gendreau, Judy Gendreau, Ashild Peters, Perry Peters, Amy Forst, Jean Engels, Seth Lederman

Including Suicidal Individuals in Treatment Trials: Treatment of Military-Related PTSD with TNX-102 SL, a Novel Sublingual Formulation of Cyclobenzaprine Hypothesized to Address PTSD through Improvement in Sleep Quality

Presented at the American Society of Clinical Psychopharmacology in Miami Beach, FL May 29 – June 1, 2018
ASCP Workshop: Inclusion of Suicidal Individuals in Treatment Trials: Now is the Time

Seth Lederman, Gregory Sullivan, Judy Gendreau, Ashild Peters, Perry Peters,

Efficacy and Safety of a Low Dose, Bedtime, Proprietary, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL#) for the Treatment of Military-Related PTSD: Study Protocol of a Phase 3 Randomized Placebo-Controlled Trial (P301)

Presented at the Military Health System Research Symposium (MHSRS) in Kissimmee, FL August 27-30; MHSRS-17-1626 Poster Session 2 - Poster #519, 10:00 AM - 4:30 PM EDT, Florida Exhibit Hall D-F

Gregory M. Sullivan, Helen Stillwell, Florence Porterfield, Judy Gendreau, R. Michael Gendreau, Ashild Peters, Perry Peters, Seth Lederman

Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response

Presented at the Military Health System Research Symposium (MHSRS) in Kissimmee, FL August 27-30; MHSRS-17-1685 Poster Session 2 - Poster #521, 10:00 AM - 4:30 PM EDT, Florida Exhibit Hall D-F

Gregory M. Sullivan, Helen Stillwell, Florence Porterfield, Judy Gendreau, R. Michael Gendreau, Ashild Peters, Perry Peters, Seth Lederman

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

Poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami, FL on June 1, 2017

Gregory Sullivan, Judy Gendreau, R Michael Gendreau, Jean Engels, Perry Peters, Ashild Peters, Seth Lederman

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

Poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami, FL on June 1, 2017

Gregory Sullivan, Judy Gendreau, R Michael Gendreau, Jean Engels, Perry Peters, Ashild Peters, Seth Lederman